Spiramycinisamacrolideantibioticthatisclinicallyusedtotreattoxoplasmosisandothersofttissueinfections.SpiramycinexhibitsantibacterialefficacyagainstToxoplasma,inhibitingbacterialproteinsynthesis.Invitro,spiramycindecreaseslevelsofIL-10andTNF-α,andinvivo,itdecreasesToxoplasma-inducedbraincysts.
| CasNo. | 11034-40-5 |
|---|---|
| Purity | ≥90% |
| Synonym | SpiramycinADIpate;stomamycin;suanovil |
| Solubility | Solubleinmostorganicsolvents. |
| Appearance | Slightlyyellowishorwhitepowder |
| StoreTemp | -20°C |
|---|---|
| ShipTemp | Ambient |
| InfoSheet | S6233InfoSheetPDF |
|---|
KiefferF,WallonM.Congenitaltoxoplasmosis.HandbClinNeurol.2013;112:1099-101.PMID:23622316.
BüyükbabaBoralO,SönmezTamerG,KeçeliÖzcanS,etal.Investigationofcombinedeffectivenessofspiramycinandbeta-glucaninmicemodelsofacutetoxoplasmosisanddeterminationofIL-10,IL-12andTNF-αlevels.MikrobiyolBul.2012Jul;46(3):446-55.PMID:22951656.
ChewWK,SegarraI,AmbuS,etal.SignificantreductionofbraincystscausedbyToxoplasmagondiiaftertreatmentwithspiramycincoadmiNISTeredwithmetronidazoleinamousemodelofchronictoxoplasmosis.AntimicrobAgentsChemother.2012Apr;56(4):1762-8.PMID:22271863.
